Abstract: A method for image dehazing based on adaptively improved linear global atmospheric light of a dark channel. A haze image in haze weather is first obtained, a variation angle of atmospheric light of the image is obtain through calculating a slope of a connection line between a center and a center of gravity of a binary image of the image, a linear atmospheric light map that varies regularly along a variation direction of the atmospheric light is obtains, a dehazed image is solved through an atmospheric scattering model, and then a processed haze image taken in the haze weather is output.

Abstract: A furniture accessory may include an armrest body and an insertion plate moveably coupled to the armrest body and configured for mounting to a furniture item. A moveable cover plate may provide access to a hollow interior of the armrest body. The furniture accessory may include a power output assembly for receiving and providing power to a detachable electrical accessory. The furniture accessory may include a power input interface and a power supply circuit for providing power from an external power source to the power output interface.

Abstract: An input method for an electronic device comprises steps of retrieving operation data according to a touch point made by a user on an input interface; generating a pending input pattern in response to the operation data of the touch point; retrieving a matched character corresponding to the pending input pattern, in response to a defined mapping relation of a plurality of input patterns and a plurality of characters; outputting the matched character.

Abstract: Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a PARP inhibitor, particularly, (R)-2-fluoro-10a-methyl-7,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(5H)-one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a chemotherapeutic agent. Also, disclosed a pharmaceutical combination comprising a PARP inhibitor, particularly, (R)-2-fluoro-10a-methyl-7,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(5H)-one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a chemotherapeutic agent and the use thereof.

Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.

Abstract: The present invention discloses a molecular sieve and its preparation method. The molecular sieve has micromorphology in a football shape and consists of molecular sieve framework and active elements. The molecular sieve framework comprises silicon element and aluminum element; the active elements comprise copper element and rare earth elements. The rare earth elements are one or more selected from the group consisting of La, Ce, Pr, Nd, Pm, Sm, Eu, Sc and Y. The mass ratio of the silicon element to the aluminum element is 3-9:1. The content of the copper element in the molecular sieve is 1.5-3.2 wt %. The mass of rare earth elements is 50 ppm-2 wt % of the molecular sieve framework. The mass of the silicon element is calculated by silicon dioxide, the mass of aluminum element is calculated by aluminum oxide, the mass of copper element is calculated by copper oxides, and the mass of rare earth elements is calculated by rare earth oxides.

Abstract: Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent. Also, disclosed a pharmaceutical combination comprising a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a targeted therapy agent and the use thereof.

Abstract: A method for preparing an SCR catalyst may include: (1) placing a first aqueous solution containing a titanium oxide and a tungstate in an electric field environment, adjusting the pH value of the first aqueous solution, and adjusting the current direction of the electric field environment to obtain a first mixture; (2) providing a second mixture by, in the electric field environment, adding dropwise a second aqueous solution containing a soluble salt of one or more active components, a copper-organic polyamine complex and a dispersant to the first mixture, and adjusting the current direction; and (3) processing the second mixture to obtain the SCR catalyst. The one or more active components may be selected from Ce, Zr, Cu, Fe, Pr and Sc.

Abstract: In one example, this disclosure is directed to a system configured to detect inclement weather in the travel path of a vehicle, determine a recommended maneuver to avoid the inclement weather, and determine the feasibility of the recommended maneuver with respect to any nearby vehicles.

Abstract: Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.

Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.

Abstract: A method for image dehazing based on adaptively improved linear global atmospheric light of a dark channel. A haze image in haze weather is first obtained, a variation angle of atmospheric light of the image is obtain through calculating a slope of a connection line between a center and a center of gravity of a binary image of the image, a linear atmospheric light map that varies regularly along a variation direction of the atmospheric light is obtains, a dehazed image is solved through an atmospheric scattering model, and then a processed haze image taken in the haze weather is output.

Abstract: A computer mouse includes at least one first fingerprint recognition device disposed on an outside surface of the computer mouse, and configured to recognize fingerprint data; and an output converting unit connected to the first fingerprint recognition device, wherein a mapping relation of a plurality of fingerprint data and a plurality of output characters is pre-stored in the output converting unit, and one of the output characters is outputted, by the output converting unit, in response to the received fingerprint data coming from the first fingerprint recognition device.

Abstract: Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.

Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) ligand (PD-L1) and inhibit PD-L1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD-L1-mediated functions.

Abstract: Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.

Abstract: Provided herein are DNA-glycan conjugates that include a glycan and a covalently attached polynucleotide. The polynucleotide includes a plurality of modules. Each module includes a nucleotide string, and the plurality of modules includes a monomer module that corresponds to each carbohydrate monomer present in the DNA-glycan conjugate, and a linkage module that corresponds to each glycosidic linkage present between each carbohydrate monomer in the DNA-glycan conjugate. The nucleotide sequence of the plurality of modules corresponds to the glycan structure. Also provided herein are methods for making and using the DNA-glycan conjugates. Further provided is a computer-implemented method for translating data from a nucleotide sequence to a glycan structure, a system for converting data from a glycan structure to a nucleotide sequence, and a system for translating data from a nucleotide sequence to a glycan structure.

Abstract: Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.

Abstract: A method for preparing an SCR catalyst may include: (1) placing a first aqueous solution containing a titanium oxide and a tungstate in an electric field environment, adjusting the pH value of the first aqueous solution, and adjusting the current direction of the electric field environment to obtain a first mixture; (2) providing a second mixture by, in the electric field environment, adding dropwise a second aqueous solution containing a soluble salt of one or more active components, a copper-organic polyamine complex and a dispersant to the first mixture, and adjusting the current direction; and (3) processing the second mixture to obtain the SCR catalyst. The one or more active components may be selected from Ce, Zr, Cu, Fe, Pr and Sc.

Abstract: Disclosed herein is a method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a PARP inhibitor, particularly, (R)-2-fluoro-10a-methyl-7,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(5H)-one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a chemotherapeutic agent. Also, disclosed a pharmaceutical combination comprising a PARP inhibitor, particularly, (R)-2-fluoro-10a-methyl-7,8,9,10,10a,11-hexahydro-5,6,7a,11-tetraazacyclohepta[def]cyclopenta[a]fluoren-4(5H)-one, a sesqui-hydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor, or a chemotherapeutic agent and the use thereof.